| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S14094 R55446 |
Ishikawa - Methyldopa (Controls unexposed, disease free), 2023 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
1.65 [0.83;3.29] C excluded (control group) |
9/93 4,519/74,213 | 4,528 | 93 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14095 R55447 |
Ishikawa - Methyldopa (Controls unexposed, sick), 2023 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 1.41 [0.68;2.93] C | 9/93 71/1,007 | 80 | 93 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13390 R51884 |
Hoeltzenbein - Methyldopa (Controls unexposed, disease free), 2017 | Major birth defects | at least 1st trimester | prospective cohort | unexposed, disease free | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 1.24 [0.40;4.00] | 9/246 12/483 | 21 | 246 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13475 R51973 |
Nakhai-Pour - Centrally acting, 2010 | Major malformations | 1st trimester | nested case control | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 1.76 [0.40;7.71] C | 2/17 4,153/59,016 | 4,155 | 17 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14186 R55706 |
Redman - Methyldopa, 1976 | Significant congenital abnormalities | during pregnancy (anytime or not specified) excluded | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified |
1.02 [0.06;16.53] C excluded (exposition period) |
1/101 1/103 | 2 | 101 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.41 [0.80;2.50] | 4,256 | 356 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, disease free;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 14094